16 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 16 of 16 clinical reviews.
GLP-1 receptor agonists have been in clinical use since 2005. This evidence-based review covers the full safety record, major trials, FDA warnings, and what patients starting these medications should know.
Mounjaro (tirzepatide) is not approved for general weight loss in all adults. Learn who qualifies, who should avoid it, what the clinical data show, and how to find out if you are a candidate.
GLP-1 receptor agonists slow gastric emptying, which can reduce or delay the absorption of oral medications taken at the same time. Learn which drugs are most affected, what the clinical data show, and how to time your medications safely.
Levothyroxine restores thyroid hormone levels in hypothyroidism, which can reverse the weight gain caused by a slow metabolism. But for people with normal thyroid function, it does not produce meaningful fat loss and carries real risks. Read the full clinical picture.
Yes, menopause can cause hair loss. Falling estrogen and progesterone levels shift hair follicles into a resting phase while rising androgen activity shrinks them. Learn the mechanisms, treatment options, and what the evidence actually shows.
Learn the clinical signs, lab markers, and evidence-based strategies to identify a slowing metabolism, including thyroid function, hormonal changes, and actionable next steps.
Body-type dieting lacks clinical evidence. Learn what actually predicts dietary success, including thyroid function, insulin sensitivity, and metabolic markers, plus how to match your eating pattern to your biology.
After 40, hormonal shifts, muscle loss, and metabolic slowdown make standard calorie-cutting ineffective. Learn what the clinical evidence actually supports for sustainable fat loss at this life stage.
Learn how to interpret TSH, free T4, free T3, testosterone, estradiol, and other hormone lab values. Understand reference ranges, optimal zones, and when results signal a need for treatment.
A guide to every major safety warning for Zepbound (tirzepatide), including the boxed warning for thyroid C-cell tumors, pancreatitis risk, gallbladder events, and renal injury.
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management. Learn about dosing, clinical trial results, side effects, cost, and how it compares to semaglutide.
A complete guide to the blood tests and lab panels your doctor may order before a metabolic health, weight management, or hormone therapy appointment, including thyroid, lipid, glucose, and hormone panels.
A guide to Wegovy® (semaglutide 2.4 mg) eligibility: BMI cutoffs, weight-related conditions, contraindications, lab workup, and how telehealth programs like Calibrate fit in.
A detailed clinical breakdown of who cannot safely use Ozempic® (semaglutide), covering absolute contraindications, relative contraindications, off-label use limits, and what your prescriber checks before writing the script.
A guide to absolute contraindications, relative cautions, and high-risk populations for GLP-1 receptor agonist therapy, including semaglutide and tirzepatide.
Hormonal shifts, muscle loss, thyroid changes, and metabolic adaptation make cookie-cutter diets fail after 35. Learn the science and what actually works.